Le Lézard
Classified in: Health, Science and technology
Subject: FDA

ScreenPoint Medical's new Transpara powered by Fusion AI cleared for 2D and 3D mammography in the USA

WASHINGTON, June 15, 2021 /PRNewswire-PRWeb/ -- The latest version of Transpara, the leading AI system that identifies potential breast cancers faster and earlier than before, has been cleared after rigorous investigation by the FDA. Transpara is already CE marked.
Transpara, developed by ScreenPoint Medical, is in daily use in over 200 healthcare facilities in more than 25 countries around the world.

Transpara powered by FusionAItm is the new platform which sets the standard for breast AI supported by clinical evidence. A fusion of knowledge: pathology, clinical imaging, X-ray physics and the latest deep learning techniques, uniquely combined by the scientists at ScreenPoint Medical in collaboration with our clinical partners.

Latest clinical studies have confirmed major new benefits for radiologists and their patients including:

Dr Rachel Brem, Medical Advisor to ScreenPoint Medical said, "The rigorous tests and training that ScreenPoint applies to Transpara are why this transformational approach to optimize the detection of early curable breast cancer is translated to our clinical practice every day. The ability to detect breast cancer, often a full year earlier, will undoubtedly impact survival from breast cancer. 95% of women diagnosed with early-stage breast cancer survive and thrive. In addition, early-stage treatment can be less invasive for patients. This improved patient care is coupled with more rapid study interpretation.

Therefore, the clinical benefits that we and our patients realize when Transpara is used is compelling to integrate Transpara to our clinical protocol."

Nicki Bryan VP at ScreenPoint Medical added, "Transpara powered by FusionAI takes deep learning artificial intelligence for 2D and 3D mammography to a whole new level opening up new possibilities in terms of efficiency and workflow savings to help in this post COVID recovery period."

"It is very exciting to see how quickly our solution has developed and hear consistent positive feedback from our customers. Feedback like they are catching cancers with the help of Transpara that they might otherwise have missed."

Albert Gubern Merida, Chief Technical Officer at ScreenPoint Medical said, "Transpara powered by Fusion AI is a huge step forward. It defines a new benchmark for breast AI for both 2D and 3D, as demonstrated by an unprecedented range of clinical evidence. And, what's even more exciting, we have only just begun. The design of this new software will allow us to further expand its capabilities in the near future, not only in terms of algorithms performance and additional features, but also on deployment aspects to ease the implementation of this breast AI technology."

FDA approval number K210404

About ScreenPoint Medical

ScreenPoint Medical is the leading developer of AI-driven image analysis technology which enables the automated reading of mammograms and digital breast tomosynthesis examinations. With proven accuracy at least matching that of experienced radiologists, ScreenPoint's Transpara system is the most advanced available, exploiting big data, deep learning and the latest advances in artificial intelligence. The system can identify high-risk breast lesions quickly, enabling earlier detection, earlier treatment and a greater chance of survival. For more information, visit https://screenpoint-medical.com/.

For more information contact:

David Lee



SOURCE ScreenPoint Medical

These press releases may also interest you

at 05:50
The "Global Behavioral Analytics Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering. The Global Behavioral Analytics Market is expected to grow at a CAGR of more than 40% during the forecast...

at 05:50
A Nomination Committee consisting of members appointed by the three largest shareholders or group of shareholders and the Chairman of the Board of Directors has been formed for Biotage AB in accordance with the principles adopted by the annual...

at 05:30
The "Bangladesh Buy Now Pay Later 2021" report has been added to ResearchAndMarkets.com's offering. According to the Q2 2021 BNPL Survey, BNPL payment in the country is expected to grow by 71.5% on annual basis to reach US$ 222.4 million in 2021....

at 05:15
EQONEX, the crypto exchange of Nasdaq-listed Eqonex Limited , today announces it has listed the Polkadot (DOT) token on its platform. The Polkadot network is a "game changing" viable alternative to Ethereum according to research published...

at 05:12
Elbit Systems ("the Company") announced today that it will commence a project to establish power generation and energy storage units at several of the Company's facilities in Israel. As part of this project, Elbit Systems will increase the volume of...

at 05:10
ReImagine Science will host its second TEDxReImagineScience event, as part of TED Countdown, on November 6th, 2021. ReImagine Science is proud to continue its role facilitating public conversation about the next era of science. Countdown, launched...

News published on 15 june 2021 at 09:00 and distributed by: